Business Context and Reporting Period
This Form 8-K filing by Lucid Diagnostics Inc. (LUCD) covers the event date of December 19, 2024. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York. The filing addresses a regulatory matter concerning the listing status of its common stock on The Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate governance and listing compliance event.
Material Changes
The material change reported is the extension of the compliance period regarding Nasdaq listing standards. Specifically:
- Initial Non-Compliance: On June 21, 2024, the company was notified that its closing bid price had been below the $1.00 minimum requirement for 30 consecutive business days.
- Extension Granted: Although the company did not regain compliance by the initial deadline of December 18, 2024, Nasdaq granted an additional 180 calendar days to regain compliance.
- New Deadline: The new compliance period extends until June 16, 2025.
Outlook, Risks, and Management Commentary
Compliance Requirements: To regain compliance, the closing bid price of the common stock must be at least $1.00 per share for a minimum of ten consecutive business days within the additional 180-day period.
Management Intent: The company intends to consider all available options to regain compliance with Nasdaq listing standards.
Current Status: The Nasdaq notification has no immediate effect on the listing of the common stock. Trading will continue uninterrupted under the symbol "LUCD."
Risks: Failure to meet the $1.00 bid price requirement within the extended period could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of LUCD stock relative to the $1.00 threshold.
- Monitor the stock price trajectory to ensure it meets the requirement of $1.00 for ten consecutive business days before June 16, 2025.
- Review future filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Confirm that no other regulatory actions or delisting notices have been issued subsequent to this filing.